Arog Pharmaceuticals names senior vice president of clinical development

Dallas-based oncology drug development company Arog Pharmaceuticals, Inc. named Ada Braun senior vice president of clinical development on Monday.

Braun previously was chief medical officer at Biothera, where she was responsible for the clinical and regulatory development of the biotechnology company's investigational immunotherapeutic drug Imprime PGG.

In her new role at Arog, Braun will in charge of clinical development and regulatory strategy for its cancer-killing treatments including its leading compound known as crenolanib, intended to treat numerous types of cancer such as acute myeloid leukemia (AML). The drug is an oral benzimidazole Type I kinase inhibitor that interferes with the signaling of wild-type and mutant isoforms of Class III receptor tyrosine kinases FLT3 and PDGFR.

Before working at Biothera, Braun was executive medical director of global development in the hematology/oncology division of biotechnology company Amgen.

"We are pleased to welcome Dr. Braun to Arog at this critical stage in our company's growth," Arog Pharmaceuticals CEO Vinay Jain said. "Dr. Braun's extensive academic and industry experience in clinical development and her proven track record of execution make her the ideal choice to lead our clinical programs as we prepare to advance our pipeline of oncology treatments."